Amylyx shares fall despite positive Phase 3 trial results for avexitide

What happened

Amylyx Pharmaceuticals, a company focused on developing treatments for metabolic and neurological diseases, announced on August 18, 2026 positive topline results from its Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia (PBH), according to a company press release cited by web sources.

The trial met its FDA-agreed primary endpoint, showing a 55% reduction in composite Level 2 and 3 hypoglycemic events versus placebo (p=0.000003). All secondary endpoints were also met, and the safety profile was favorable. The company plans to submit a New Drug Application (NDA) to the FDA by year-end 2026.

Despite the positive news, the stock closed at $38.66 on August 18, down 2.52% from the previous close of $39.66, according to price data.

The primary source of the results is a company announcement, relayed in investor posts on X (e.g., @semodough) and corroborated by a press release on Amylyx's investor relations page and coverage by Yahoo Finance, StockTitan, GuruFocus, Investing.com, TipRanks, and The Fly.

Why it matters

The positive pivotal data materially de-risks avexitide, Amylyx's lead asset, which holds Breakthrough Therapy and Orphan Drug designations from the FDA. Meeting the primary endpoint and all secondary endpoints supports the company's path toward an NDA submission.

The stock decline, despite the positive results, may reflect that the outcome was anticipated by the market, but the provided sources do not explain the price move.

What this means

A Phase 3 trial is the final stage of clinical testing before a company can seek regulatory approval. The LUCIDITY trial's primary endpoint was the reduction in Level 2 and 3 hypoglycemic events, which are episodes of dangerously low blood sugar that can cause serious symptoms or require assistance. A 55% reduction versus placebo is the key measure of avexitide's effectiveness.

Post-bariatric hypoglycemia is a complication that can occur after weight-loss surgery, where patients experience low blood sugar after eating. Avexitide is a peptide designed to block a hormone that stimulates insulin secretion, thereby preventing the blood sugar drops.

The company's plan to submit an NDA by year-end 2026 indicates it will ask the FDA to approve avexitide for PBH. If approved, it could become a new treatment option for this condition. The FDA granted Breakthrough Therapy and Orphan Drug designations, which are intended to expedite development and review for serious conditions with unmet need.

The NDA submission and potential approval are not guaranteed; the FDA will review the data independently. The stock's drop on the announcement day is not explained by the sources; it may reflect investor expectations or other market factors.

Note: Amylyx reported no revenue for the year ending December 31, 2025, according to the data provided, indicating the company is pre-commercial and relies on trial results for its valuation.